Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
15 Maio 2023 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION
UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File No. 001-35817
Vyant
Bio, Inc.
(Exact
name of registrant as specified in its charter)
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(201)
479-1357
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common
Stock, par value $0.0001 per share
(Title
of each class of securities covered by this Form)
None
(Titles
of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule
12g-4(a)(1) |
☒ |
Rule
12g-4(a)(2) |
☐ |
Rule
12h-3(b)(1)(i) |
☒ |
Rule
12h-3(b)(1)(ii) |
☐ |
Rule
15d-6 |
☐ |
Rule
15d-22(b) |
☐ |
Approximate
number of holders of record as of the certification or notice date: 71
Pursuant
to the requirements of the Securities Exchange Act of 1934, Vyant Bio, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
|
VYANT
BIO, INC. |
|
|
|
By: |
/s/
Andrew D. C. LaFrence |
|
Name: |
Andrew
D. C. LaFrence |
|
Title: |
President,
Chief Executive Officer and Chief Financial Officer |
|
|
|
Date:
May 15, 2023 |
|
|
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Cancer Genetics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Vyant Bio, Inc.